FDA Brief

Warning letters Biologics

FDA warning letter to

Chara Biologics, Inc.

High riskIssued Jan 17, 2025Posted Jan 28, 2025Center for Biologics Evaluation and Research (CBER)

FDA warns Chara Biologics over unapproved, unlicensed CharaExo, CharaCore, CharaOmni.

What happened

FDA inspected Chara Biologics’ Chatsworth, CA facility from July 23 to August 16, 2024, and reviewed the firm’s websites, brochures, and physician materials. FDA found CharaExo, CharaCore, and CharaOmni promoted for many diseases without an approved BLA or IND, plus CGMP/CGTP violations and unsupported expiration-date extensions for CharaExo.

What FDA found

  1. FDA says the products are unapproved new drugs and unlicensed biological products because no BLA or IND is in effect.

    FD&C Act section 505(a), 21 U.S.C. § 355(a); PHS Act section 351(a)(1), 42 U.S.C. § 262(a)(1)
  2. FDA says the firm lacked a quality unit with authority to approve or reject labeling and drug products and lacked written quality-unit procedures.

    21 CFR 211.22(a) and 211.22(d)
  3. FDA says Chara did not keep donor-eligibility determination records, including the responsible person’s name and the date, for umbilical cord donors.

    21 CFR 1271.55(d)(1)(iii)
  4. FDA says CharaExo labeling was false or misleading because the firm extended expiration dates by one year or more without supporting data.

    FD&C Act section 502(a), 21 U.S.C. § 352(a)
  5. FDA says CharaCore and CharaOmni failed HCT/P criteria for minimal manipulation and homologous use, so they are regulated as drugs and biological products.

    21 CFR 1271.10(a)(1), (a)(2); 21 CFR 1271.3(f)(1), (c)

What FDA wants

FDA asks Chara to respond in writing within 15 working days with specific corrective steps, documentation, and plans for inventory and distributed products. If it cannot meet that timeframe, it must explain the delay and give a completion date.

Who should pay attention

  • clinics and physicians buying or using Chara products
  • brands that buy or distribute HCT/P or biologic products from contract manufacturers
  • quality teams managing donor eligibility and labeling for cell/tissue products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Beaute Bounty

    FDA warns Beaute Bounty that its stem cell and placenta products are unapproved drugs and unlicensed biologics.

    High risk
  2. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  3. Blue Horizon International, LLC

    FDA warned Blue Horizon International over unapproved stem cell and exosome biologics marketed for serious diseases without a license.

    High risk
  4. Dynamic Stem Cell Therapy

    FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

    High risk